Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Operating Leases (2024 - 2025)

Prelude Therapeutics' Operating Leases history spans 2 years, with the latest figure at $17.8 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 16.08% year-over-year to $17.8 million; the TTM value through Dec 2025 reached $17.8 million, up 16.08%, while the annual FY2025 figure was $17.8 million, 16.08% up from the prior year.
  • Operating Leases for Q4 2025 was $17.8 million at Prelude Therapeutics, up from $15.2 million in the prior quarter.
  • Across five years, Operating Leases topped out at $18.2 million in Q2 2024 and bottomed at $15.2 million in Q2 2025.